Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
Alterity Therapeutics filed a Form 6-K sharing a new peer‑reviewed publication and pipeline update for its Multiple System Atrophy (MSA) program. The study in NeuroImage shows that quantitative susceptibility mapping (QSM) MRI can detect disease‑specific iron accumulation in MSA, distinguish it from Parkinson’s disease, and track clinical severity, including early‑stage disease.
The research drew on longitudinal bioMUSE Natural History Study data and additional MSA, Parkinson’s and healthy control participants, supporting QSM as an objective imaging biomarker for iron‑modulating therapies such as Alterity’s lead candidate ATH434. Alterity notes that ATH434 showed robust clinical efficacy, target engagement and a favorable safety profile in Phase 2 trials and has Fast Track and Orphan Drug Designations. The company is advancing ATH434 toward a pivotal Phase 3 trial in MSA and plans an End‑of‑Phase 2 meeting with the FDA in mid‑2026.
Alterity Therapeutics Limited reports that presentations on its development program for Multiple System Atrophy (MSA) will be delivered at several medical conferences in May 2026. These include the International Society for Magnetic Resonance in Medicine annual meeting, the Movement Disorder Society of Australia and New Zealand meeting, and the MSA Symposium 2026.
The company describes itself as a clinical stage biotechnology firm focused on disease modifying therapies for MSA and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA. Its lead asset, ATH434, has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in advanced MSA.
Alterity Therapeutics reported its Q3 FY26 cash flow and corporate update, highlighting progress toward a Phase 3 trial of ATH434 for Multiple System Atrophy (MSA). The company received written Type C feedback from the U.S. FDA on clinical pharmacology, non-clinical, and CMC elements, supporting its pivotal development plans and an End-of-Phase 2 meeting targeted for mid-2026.
New analyses from the ATH434-201 Phase 2 trial using the MuSyCA composite scale showed ATH434 slowed disease progression versus placebo, with treatment effects of −1.9 points at 75 mg and −4.0 points at 50 mg (p=0.034, 41% relative effect) at Week 52. Alterity strengthened its team by appointing Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor and Ann Cunningham as an independent Non-Executive Director.
The company reported cash and cash equivalents of A$44.53 million as of 31 March 2026 and operating cash outflows of A$4.73 million for the quarter, implying about 9.4 quarters of funding at the current burn rate. Management continues strategic partnering discussions for ATH434 and active engagement with investors and medical key opinion leaders.
ALTERITY THERAPEUTICS LTD director Ann Michelle Cunningham has filed an initial Form 3 insider ownership report. The filing lists her as a director but shows no reported transactions or derivative positions, indicating this is a baseline disclosure of her status rather than an update to prior trading activity.
Alterity Therapeutics Limited has called an online general meeting on 29 May 2026 to vote on several governance and capital-structure changes. Shareholders will consider electing directors Julian Babarczy and Ann Cunningham, a 50:1 consolidation of shares and options, and adjustments to the company’s ADR ratio. The meeting will also vote on issuing up to 100,000,000 options (pre-consolidation) to Mr Babarczy and up to 50,000,000 options to Montoya Pty Ltd ATF Buttercup Trust, an entity associated with director Lawrence Gozlan. In addition, shareholders are asked to lift the employee incentive issue cap to 10% of issued capital and approve issuing up to 1,087,541,633 securities (pre-consolidation) under the Employee Incentive Securities Plan.
Alterity Therapeutics Limited reports that the U.S. FDA has provided positive regulatory feedback in a second Type C Meeting on its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA). The agency and company reached alignment on key chemistry, manufacturing, and control (CMC) elements, supporting readiness for Phase 3 initiation while manufacturing scale-up progresses in parallel. An End-of-Phase 2 meeting with the FDA remains on track for mid-2026, positioning ATH434 for a pivotal trial in this rare, rapidly progressive neurodegenerative disease with no approved disease-modifying treatments.
Alterity Therapeutics reported new analyses from its Phase 2 trial of ATH434 in Multiple System Atrophy, showing signals of clinical efficacy. Using the new MuSyCA composite scale, placebo patients worsened by about 9.7 points over 52 weeks, while ATH434 slowed progression by 1.9 to 4.0 points, with a 41% relative treatment effect at the 50 mg dose. A separate analysis using modified UMSARS Part I found ATH434 reduced decline versus placebo by 3.1 points at 75 mg and 4.7 points at 50 mg, with relative treatment effects of 35% and 53% and a statistically significant p-value at the lower dose. The company says these findings support ATH434’s disease-modifying potential and its plans to advance into a Phase 3 pivotal trial in MSA.